Get the Stockscreener App
7.135
0.76%
-0.055
After Hours:
7.14
0.005
+0.07%
Ataibeckley Inc stock is traded at $7.135, with a volume of 13.81M.
It is down -0.76% in the last 24 hours and up +75.74% over the past month.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
See More
Previous Close:
$7.19
Open:
$7.165
24h Volume:
13.81M
Relative Volume:
1.25
Market Cap:
$2.64B
Revenue:
$3.49M
Net Income/Loss:
$-663.48M
P/E Ratio:
-3.1871
EPS:
-2.2387
Net Cash Flow:
$-115.08M
1W Performance:
+25.84%
1M Performance:
+75.74%
6M Performance:
+82.95%
1Y Performance:
+102.12%
1-Day Range:
$7.13
$7.21
1-Week Range:
$5.30
$7.22
52-Week Range:
$3.06
$7.22
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
1 929 207 2670
Address
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.135 | 2.66B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
482.00 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
675.19 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
874.74 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.29 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.37 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Deutsche Bank | Buy |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Lilly-AtaiBeckley Deal A Stamp Of Approval For Psychedelics - Law360
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? - PR Newswire
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal - Investing.com UK
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal By Investing.com - Investing.com Australia
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
Eli Lilly Acquires AtaiBeckley to Expand Mental Health Treatment Pipeline in $3.8 Billion Deal - Global Legal Chronicle
AtaiBeckley (NASDAQ:ATAI) shares reflect 18% implied value for acquisition milestone entitlements - TechStock²
ATAIBECKLEY INC : BERENBERG CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $7.45 FROM $14 - Bitget
AtaiBeckley (ATAI) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
ATAIBECKLEY INC : TD COWEN CUTS TO HOLD FROM BUY - Bitget
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside - TradingView
Berenberg Downgrades AtaiBeckley to Hold From Buy, Adjusts Price Target to $7.45 From $14 - Moomoo
TD Cowen Downgrades AtaiBeckley to Hold From Buy - marketscreener.com
Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3 - TradingView
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - TradingView
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week? - TradingView
AtaiBeckley (NASDAQ:ATAI) shares trade with Merger CVR valued near 19% of face - TechStock²
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Eli Lilly (LLY) to Acquire AtaiBeckley for $2.8B - GuruFocus
Berenberg Bank Sticks to Their Buy Rating for Atai Beckley N.V. (ATAI) - The Globe and Mail
Maxim Group Maintains AtaiBeckley(ATAI.US) With Hold Rating - Moomoo
Eli Lilly psikedelik ilaç üreticisi AtaiBeckley’yi 2,8 milyar dolara satın alıyor; zihinsel hastalık tedavilerinde yeni seçeneklerin devreye girmesi bu satın almanın gündeme gelmesinde önemli bir etken. Bu satın almayla Lilly, AtaiBeckley’nin deneysel DMT bazlı ila - instagram.com
TD Cowen Downgrades AtaiBeckley(ATAI.US) to Hold Rating - Moomoo
Form 13D/A AtaiBeckley Inc. For: 17 July By Investing.com - Investing.com Canada
AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal - Stock Titan
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc.ATAI - Business Wire
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion - Benzinga
A Quick Look at Today's Ratings for AtaiBeckley(ATAI.US), With a Forecast Between $7.5 to $8 - Moomoo
Eli Lilly Expands with $2.8B Psychedelic Acquisition - Investing News Network
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout - TradingView
Eli Lilly Drops $3.8 Billion on AtaiBeckley, Sending Psychedelic Stocks Soaring - finance.biggo.com
This ONEOK Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Eli Lilly agrees to $3.8B psychedelic buy - Axios
Biotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developers - QuotedData
Lilly to buy AtaiBeckley in $3.8B psychedelic push - MSN
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - TradingView
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies - Proactive financial news
AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par - TechStock²
Canaccord Genuity Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $8 From $17 - Moomoo
Eli Lilly (LLY) Is Buying AtaiBeckley To Enter Psychedelic Mental Health Treatments - simplywall.st
Jefferies Downgrades AtaiBeckley to Hold From Buy, Adjusts PT to $7.50 From $10 - marketscreener.com
Company News for July 17, 2026 - Yahoo Finance
Eli Lilly Bets Big on Psychedelics with $3.8 Billion Takeover of AtaiBeckley - EBC Financial Group
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued - Yahoo Finance
AtaiBeckley (ATAI) Surges Over 31% to Reach $7.05 - GuruFocus
Jefferies downgrades Atai stock rating to hold on Lilly buyout - Investing.com
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics - Proactive financial news
Lilly buys Europe-rooted AtaiBeckley for up to $3.8B - European Biotechnology Magazine
AtaiBeckley(ATAI) Stock Options Chain | Quotes & News - Moomoo
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday - Sahm
Biotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lilly - DirectorsTalk Interviews
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):